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ABSTRACT
Insulin resistance is an independent risk factor for heart disease. In cardiac 
muscle, PI3K-Akt signaling is persistently activated, despite a reduction in glucose 
uptake. Given that persistent activation of PI3K and Akt in the heart may be a 
consequence of hyperinsulinemia in insulin resistant states, the study in Chapter 2 
was designed to determine if constitutive activation of PI3K and Akt signaling in 
the heart could independently impair insulin-mediated glucose uptake and GLUT4 
translocation. The study was initially predicated on the hypothesis that chronic 
activation of PI3K and Akt signaling would activate mTORC1-mediated S6K-IRS 
negative feedback signaling and desensitize insulin-mediated glucose transport. 
Unexpectedly, the study discovered that PI3K and Akt activation impairs 
myocardial glucose uptake prior to any evidence of S6K activation despite normal 
translocation of GLUT4 in cardiomyocytes. These data indicate that activation of 
PI3K and Akt may impair glucose uptake via mechanisms that impair the intrinsic 
activity of the GLUT4 transporter.
Insulin signaling and many other cellular signaling pathways converge at 
mTOR, which has been intensively studied in cell culture and different mouse
tissues. However, the role of mTOR in cardiac development has never been 
studied. In Chapter 3, an inducible mTOR deficient mouse model was generated 
for studying the role of mTOR in cardiac bioenergetics. A decrease of fatty acid 
utilization, which leads to an impairment in ATP production, was identified in the 
mTOR deficient heart prior to development of cardiac dysfunction and lethality of 
the mice. Ongoing studies are focusing on the mechanisms of how mTOR 
regulates fatty acid metabolism in the heart.
Taken together, this dissertation has advanced our understanding of insulin 
signaling in regulation of glucose uptake and GLUT4 translocation in the heart, as 
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Cardiovascular disease and heart fa ilure in type II diabetic patients
Heart failure (HF) is a fatal disease with a 5-year mortality rate of about 
50%. Compared to HF, type II diabetes, a form of diabetes in which patients 
cannot respond to insulin properly (known as insulin resistance) is not lethal. But 
the complications of diabetes such as heart disease and stroke are more lethal 
and claim more deaths than diabetes itself, according to the census of U.S. death 
certificates. Mechanistically how insulin resistance predisposes and leads to HF is 
not clear, but increased inflammation due to elevated adipokines, as well as 
elevated serum glucose and triglyceride levels are well known stresses on the 
hearts in diabetic patients (1). So, compared to nondiabetic individuals, type II 
diabetics are exposed to higher risk for heart disease, even at a young age. Once 
type II diabetics develop heart diseases, the conditions are usually more severe 
and the outcomes are usually poorer.
(http://www.nhlbi.nih.gov/health/health-topics/topics/dhd/)
The heart can become insulin resistant too, whether the cardiac insulin 
resistance itself causes or contributes to heart failure is not well established, so 
studies of cardiac insulin signaling and cardiac insulin resistance have been of 
great interest to many researchers and clinicians.
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Insulin s ignaling and cardiac insu lin  resistance
Insulin is a hormone, produced by the pancreas, to regulate carbohydrate 
and fat metabolism. Insulin stimulates cells in the metabolic organs such as liver, 
muscle, and adipose tissue to take up glucose from the blood, storing it 
as glycogen inside the cells. Insulin signaling is a complicated process involving 
coordinated activation of many kinases. First, insulin binds to the insulin receptor, 
a transmembrane tyrosine kinase which dimerizes on the cell surface (2), 
promoting a rapid conformational change that activates its tyrosine kinase domain 
(3). The activated insulin receptor auto-phosphorylates its tyrosine kinase domain 
and serves as a signaling scaffold, providing a docking site for many proteins 
including IRS proteins, Shc, and Gab-1 (growth factor receptor binding protein 1) 
(Figure 1.1).
Activated IRS proteins promote the assembly of the p85 and p110 
subunits of PI3K, which phosphorylates phosphatidylinositol 4,5-bisphosphate 
(PIP2) to phosphatidylinositol 3, 4,5 triphosphate (PIP3) (4). Production of PIP3 
recruits PDK1 (phosphoinositide-dependent kinase 1) to the plasma membrane 
for activation, which subsequently phosphorylates Akt on Thr308 residue (5). 
Thr308 phosphorylation is sufficient for Akt’s kinase activity towards a subset of 
downstream targets; however, additional phosphorylation of Ser473 residue by 
mTORC2 activates Akt towards an additional subset of targets.
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Figure 1-1: Insulin signaling and regulation of glucose transport, protein synthesis 
and glycogen synthesis by insulin. Insulin binds to the dimerized insulin receptor 
(IR) on cell surface, resulting in phosphorylation and activation of its tyrosine 
kinase domain inside the cell. Activated IR recruits SHC, Grb2, SOS, Ras and 
Raf1 to activate MEK and MAP kinase. Activated IR also recruits IRS proteins, 
which then activates PI3K, leading to phosphorylation of PIP2 to PIP3. Generation 
of PIP3 activates PDK1, which subsequently phosphorylates and activates Akt. 
Akt controls glucose transport, protein synthesis and glycogen synthesis through 
phosphorylation and regulation of AS160, TSC2 and Gsk3p, respectively.
insulin action, including insulin induced glucose uptake, glycogen synthesis, 
protein synthesis, cell proliferation, and cell survival (6). As illustrated in Figure 1.1, 
Akt phosphorylates AS160 and promotes the translocation of GLUT4 to the cell 
surface, facilitating cellular glucose uptake. Akt can also phosphorylate and 
inactivate GSK3P, which is an inhibitor of glycogen synthase (GS). So GSK3P 
phosphorylation by Akt increases glycogen synthase activity upon insulin 
stimulation. Akt directly phosphorylates TSC2 and activates mTORCI, which is a 
master regulator of protein synthesis.
The mitogen-activated protein kinase (MAPK) pathway is the other 
pathway activated by insulin (7). Insulin triggers this pathway by the recruitment 
and phosphorylation of Shc, which then recruits Grb2 (growth factor 
receptor-bound protein 2) and mSOS (mammalian son of sevenless), Ras, and 
Raf, forming a complex that phosphorylates MEK (Figure 1-1).
However, the MAPK pathway is considered more of a general signaling 
pathway that is utilized by many growth factor receptors, not merely insulin. 
Instead, the Akt-PI3K pathway mediates most of the metabolic signaling that is 
stimulated by insulin. Last, although most of the studies were initially done in 
noncardiomyocytes, much evidence suggests this signaling pathway operates 
robustly in cardiomyocytes.
As previously defined, insulin resistance is a pathophysiological condition 
in which organs fail or become less responsive to insulin. Insulin resistance in
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muscle (skeletal and heart) and fat cells reduces glucose uptake, whereas insulin 
resistance in liver cells decreases glycogen synthesis and storage, and fails to 
suppress glucose production and release into the blood, both contributing to an 
elevation of blood glucose. Insulin resistance in fat cells also reduces uptake of 
circulating lipids and increases hydrolysis of stored triglycerides, resulting in an 
increase of free fatty acids in the blood. Molecular mechanisms of insulin 
resistance are generally thought to be linked to a reduction in insulin stimulated 
PI3K-Akt signaling, especially in skeletal muscles (8).
However, cardiac insulin resistance is characterized by a decrease of basal 
and insulin stimulated cardiac glucose transport that is associated with an 
increase of cardiac PI3K-Akt signaling (9, 10). At the onset of type II diabetes, the 
pancreas produces more insulin to compensate for unresponsiveness in other 
organs, resulting in a hyperinsulinemia, which may contribute to an increase of 
Akt-PI3K signaling in the heart. In skeletal muscle and liver, PI3K-Akt signaling 
activates mTORC1, which increases the phosphorylation of S6K1, a kinase that 
phosphorylates IRS1 protein at multiple sites including Ser1101 (11) and 
promotes IRS1 degradation through the ubiquitin-proteasome pathway (12). This 
S6K1-IRS negative feedback pathway has been shown to affect both metabolic 
diseases and aging, and deletion of S6K1 protein protects mice from high fat diet- 
or aging-induced insulin resistance in liver and skeletal muscle (13). Whether 
elevated PI3K-Akt signaling activates this mTORC1-S6K1-IRS negative feedback
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pathway in the heart and leads to reduced glucose uptake in the heart has not 
been established.
mTORC1 and mTORC2
Rapamycin and discovery of Target of rapamycin (TOR)
Rapamycin, also known as sirolimus, a natural product produced by the 
bacterium Streptomyces hygroscopicus, was first discovered in a soil sample 
from Easter Island and first characterized as a new antifungal antibiotic (14-17). 
Rapamycin belongs to a group of compounds called macrolides. They all share a 
macrolide ring, usually a 14-, 15-, or 16-membered macrocyclic lactone ring to 
which one or more deoxy sugars may be attached (Figure 1 -2).
Rapamycin was later found to have an immunosuppressive effect and was 
developed by Wyeth (now part of Pfizer) under the trade name Rapamune as an 
immunosuppressant drug to prevent organ rejection, which was approved by the 
FDA in 1999. Rapamycin is also widely used in research, because of its 
anti-proliferation property rather than its antifungal property. In the 1990s, 
researchers identified two target rapamycin genes (TOR1 and TOR2) in a budding 
yeast (Saccharomyces cerevisiae) genetic screen, mutations of which allowed 
yeast to escape from cell cycle arrest caused by rapamycin treatment (18). Much 
of our knowledge about TOR proteins is based on the use of rapamycin.
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8Figure 1-2: Structural diagram of rapamycin.
There are two TOR complexes in budding yeasts: rapamycin sensitive 
complex TORC1 and rapamycin insensitive TORC2 (19). TOR2 protein can exist 
in either complex in budding yeast, but it is unique in TORC2, a complex which 
regulates the cell cycle-dependent polarization of the actin cytoskeleton (20), 
while TORC1 is mainly involved in regulation of cell growth.
TOR is highly conserved from yeast to mammals based on sequence 
comparison. However, there is only one TOR gene identified in mammals, named 
mammalian target of rapamycin—mTOR. mTOR engages in two distinct 
complexes similar to yeast: mTORC1 and mTORC2, each controls a wide 
spectrum of signaling pathways in cells. In the subsequent section 1.3.2 and 1.3.3, 
the regulation of each complex and function of each complex will be reviewed in 
detail.
Mammalian target of rapamycin complex 1 (mTORC1)
mTORC1 has five known components: complex core-mTOR protein; 
a regulatory associated protein of mTOR (Raptor) that defines mTOR’s catalytic 
substrate specificity; proline-rich Akt substrate 40 kDa (PRAS40); mammalian 
lethal with Sec13 protein 8 (mLST8); and newly found DEP-domain-containing 
protein (Deptor) which negatively regulates complex activity (21) (Figure 1-3). 









Figure 1-3: Input and output of mTORC1 and mTORC2. mTORC1 consists of 
mTOR, raptor, mLST8, PRAS40 and Deptor, whereas mTORC2 consists of 
mTOR, rictor, hSin1, mLST8, PRAS40 and Protor 1/2. Rapamycin sensitive 
mTORC1 is regulated by insulin, hypoxia, ATP or BCAA to modulate autophagy, 
protein translation and mitochondrial biogenesis; whereas regulation of mTORC2 
is not well known, and the physiological function of mTORC2 is not clear either. 
Recently it is shown that high concentration of rapamycin can also inhibit 
mTORC2.
as growth factors (insulin, IGF), energy stress, hypoxia and amino acids can 
regulate mTORC1 activity. Many of these regulations converge at the TSC1-TSC2 
complex, which functions as a GTPase-activating protein (GAP) towards Rheb 
protein. Rheb activates mTORC1 when it is in the GTP-bound state. Growth 
factors such as insulin or IGF activate Akt, leading to the phosphorylation of TSC2 
(tuberous sclerosis complex 2) on Ser 924 and Thr 1518 sites. TSC2 
phosphorylation by Akt represses GAP activity of the TSC1-TSC2 complex, 
allowing Rheb to accumulate in an active GTP-bound state. So inhibition of TSC2 
by Akt phosphorylation leads to the activation of Rheb, which subsequently 
activates mTORC1 (22).
Low cellular energy level is characterized by low ATP, high ADP and AMP 
levels. It has been shown that mTORC1 itself acts as an ATP sensor and can be 
activated directly by a high concentration of ATP (23). During energy starvation, 
AMP activates AMPK, a master sensor of intracellular energy status, which then 
directly phosphorylates TSC2 on Thr1227 and Ser1345, and inhibits mTORC1 
activation through a mechanism involving inhibition of Rheb (24-26). AMPK can 
also phosphorylate raptor on Ser722 and Ser792 to reduce mTORC1 signaling 
(27) (Figure 1-4).
Low oxygen levels can also modulate mTORC1 activity. Limitation of 
oxygen always limits mitochondrial respiration and results in a reduction of ATP 




Figure 1-4: A schematic diagram of TSC2 protein structure, it shows the 
regulation of TSC2 by Akt, AMPK and REDD1. TSC2 binds to TSC1 through its 
N-terminus, and is stabilized by TSC1. See text for regulation of TSC2 by Akt, 
AMPK and REDD1. TSC2 is a GTPase-activating protein (GAP) toward Rheb, 
activation of TSC2 leads to accumulation of Rheb in its inactive Rheb-GDP form.
Hypoxia can also stabilize HIFIa, a master regulator of the 
hypoxia-induced transcriptional response. Under normoxic conditions, H IFIa is 
hydroxylated by prolylhydroxylase domain-containing proteins (PHD) on specific 
prolyl residues, allowing it to be recognized by the von Hippel-Lindau (VHL) 
protein, and thus targeted for ubiquitin-dependent degradation (28). However 
under hypoxia, HIF1a is stabilized and accumulates in cells to increase 
transcriptional regulation of many hypoxic response genes, most notably the 
regulation of DNA damage response 1 (REDD1). REDD1 dissociates TSC2 from 
14-3-3 proteins, thereby activating the TSC1-TSC2 complex and inhibiting 
mTORCI activity (29-31) (Figure 1-4).
In summary, growth factor deprivation, low cellular energy level and 
hypoxia all suppress mTORCI by regulation of TSC2, but the detailed molecular 
mechanism differs.
Amino acids, especially branched chain amino acids (BCAA), such as 
Leucine, Iso-Leucine and Valine positively regulate mTORCI (32). The activation 
of mTORCI by amino acids is through a distinct mechanism without the 
regulation of TSC1-TSC2 complex. Withdrawal of amino acids inhibits mTORCI 
activity in the presence of growth factor stimulation.
Recently, four small GTPase-Rag proteins have been shown to form two 
heterodimeric RagA/RagC and RagB/RagD complexes, to promote the 
relocalization of cytoplasmic mTORCI to a perinuclear region where its activator
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Rheb resides in the presence of amino acids. Deprivation of amino acids induces 
the dissociation of mTORC1 and Rheb, and it cannot be overcome by growth 
factors (33, 34). This explains why growth factors cannot activate mTORC1 in the 
absence of amino acids.
Human vacuolar protein-sorting associated protein 34 (hVPS34), also 
known as class 3 PI3K has also been implicated in activation of mTORC1 by 
amino acids (35): amino acids trigger a pulse of Ca2+ release from ER to 
cytoplasm and increase the binding of Ca2+/CaM to hVps34 (36), which then 
subsequently binds to mTORC1 and activates it through a mechanism not yet 
understood (37). mTORC1 is also shown to be activated by amino acids released 
from lysosomes through a mechanism that requires the vacuolar H(+)-ATPase 
(38).
Activation of mTORC1 usually increases protein translation through two 
most-described mTORC1 downstream targets: eukaryotic initiation factor 4E 
(eIF4E)-binding protein 1 (4E-BP1) and p70 ribosomal S6 kinase 1 (S6K1). Both 
proteins regulate cap-dependent protein translation in cells.
After mRNA is transcribed, processed, and transported into the cytoplasm, 
many eukaryotic initiation factors (eIFs) including eIF4E bind to a 5’ cap of mRNA 
forming an initiation core, which recruits a 43S pre-initiation complex containing a 
40S ribosomal subunit and other eIFs. Then the 60S ribosomal unit binds to form 
a completely assembled ribosome, which scans the mRNA for the start codon
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AUG to start protein synthesis. Phosphorylation of 4E-BP1 by mTORC1 reduces 
its capability to bind to eIF4E, resulting in more eIF4E to associate with 5’ cap of 
mRNA for assembly of the protein translation initiation complex, which results in 
an increase of protein translation (39).
Phosphorylation of S6K1 by mTORC1 also leads to an increase in mRNA 
cap-dependent translation through regulation of many different proteins, such as 
programmed cell death 4 (PDCD4), eukaryotic elongation factor 2 kinase (eEF2K), 
as well as S6K1 aly/REF-like target (SKAR) (40). PDCD4 inhibits eIF4A, an RNA 
helicase that catalyzes the unwinding of secondary structure of the 5’ untranslated 
region (5’UTR) of mRNAs, possibly by preventing it from binding to eIF4G. S6K1 
phosphorylates PDCD4 on Ser67, targeting it for ubiquitin-mediated degradation 
(41), and thus promotes eIF4A activity and mRNA translation initiation. S6K1 also 
phosphorylates SKAR on Ser383/385 sites to enhance translation of spliced 
mRNAs (42). S6K1 can also phosphorylate and inhibit eEF2K to increase nascent 
peptide elongation by activating the translation elongation factor eEF2, which is 
normally suppressed by eEF2K (43). Altogether, activation of S6K1 promotes 
protein translation from mRNA (Figure 1-5).
Besides regulation of protein translation, mTORC1 has also been shown to 
suppress autophagy. Autophagy is a cellular process involving the sequestration 
of cytoplasmic components and organelles by double membrane structures that 
are subsequently targeted for lysosomal degradation. Autophagy is essential for
15
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Figure 1-5: S6K promotes protein translation through regulation of PDCD4,
SKAR and eEF2K. See text for details.
survival, development, and cellular organelle homeostasis. mTORC1 inhibits 
autophagy through phosphorylation of unc-51-like kinase1 (Ulk1) and inactivation 
of an Ulk1-Atg13-FIP200 complex, which is required for the initiation of 
autophagosome (44-46). This increase of protein translation and suppression of 
autophagy through the same mTORC1 shows a coordinated regulation of cellular 
physiology in cells.
Another important function of mTORC1 is the regulation of mitochondrial 
biogenesis and function. mTORC1 complexes with the transcription factor 
Yin-Yang-1 (YY1) and the transcriptional cofactor PGC-1a to form a 
mTORC1-YY1-PGC-1a complex that binds to promoters of various mitochondrial 
biogenesis genes including PGC-1a itself and cytochrome C (47). Inhibition of 
mTORC1 by rapamycin in C2C12 cells and in mouse skeletal muscle resulted in a 
decrease of mitochondrial gene expression and oxygen consumption.
One of the most well-known mTORC1 inhibitors is rapamycin, which 
interacts with FKBP12 to form a complex that promotes the dissociation of the 
mTORC1 complex (48). As mentioned before, most of the early research on 
mTORC1 was based on rapamycin inhibition of mTOR activity.
An endogenous mTORC1 inhibitor FKBP38 was discovered in 2007 (49): 
FKBP38 was proposed to bind to mTORC1 to suppress mTORC1 signaling. Upon 
insulin stimulation, Rheb is transformed from the GDP bound state to the GTP 
bound state by TSC1-TSC2. Rheb-GTP then binds to FKBP38, dissociating it
17
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from mTORC1, and thus activating mTORC1.
Mammalian target of rapamycin complex 2 (mTORC2)
mTORC2 consists of mTOR, rapamycin-insensitive companion of mTOR 
(Rictor), mLST8, mammalian stress-activated protein kinase interacting protein 
1 (hSin1) and the Bit61 family members PRR5 and PRR5L (also known as 
Protor1 and Protor2) (50) (Figure 1.3).
The function and regulation of mTORC2 have not been as extensively 
studied as mTORC1. mTORC2 was once thought to be the mTOR complex that is 
rapamycin insensitive. However, prolonged or high dose rapamycin treatment 
also reduces mTORC2 signaling by decreasing free mTOR proteins for the 
assembly of mTORC2 (51).
Growth factors such as insulin can activate mTORC2 by promoting the 
binding of mTORC2 to the ribosome in a PI3K-dependent manner (52). However, 
how insulin promotes the movement of the mTORC2 to the ribosome remains 
unclear.
Activated mTORC2 phosphorylates Akt on Ser473 residue (53, 54), which 
plays an important role in determining Akt’s substrate specificity; for example, 
impairment in Akt Ser473 phosphorylation by disruption of rictor (mTORC2) did 
not affect the phosphorylation of GSK3P, or TSC2 by Akt, but phosphorylation and 
the activity of various forkhead families of transcription factors (FOXOs) and Akt
substrate of 160KD (AS160) were reduced (55-57). The decrease of AS160 
phosphorylation in skeletal muscle deficient in mTORC2 was shown to impair 
insulin-stimulated glucose uptake (56). The decrease of FOXO phosphorylation 
promotes their nuclear localization and increases the transcriptional activity for 
many genes involved in autophagy in skeletal muscle (58, 59).
Although Akt phosphorylates TSC2, this does not place mTORC2 
upstream of mTORC1, because TSC2 phosphorylation is not affected by 
mTORC2 deletion. Oppositely, deletion or inhibition of mTORC1 has a positive 
effect on mTORC2 through relieving negative feedback signaling of S6K on IRS 
proteins.
After the identification of Akt as an mTORC2 substrate, many other AGC 
kinases such as PKC were also suggested being substrates of mTORC2 (60). 
However, whether PKC is directly phosphorylated by mTORC2 is not clear.
A well-established function of TORC2 in yeast is the regulation of the actin 
cytoskeleton. In cultured mammalian cells, knockdown of mTORC2 also results in 
alteration of the actin cytoskeleton and an increase of stress fibers (60-62). 
However, ablation of Rictor in mice renders no obvious alteration in the actin 
cytoskeleton, raising a question whether mTORC2 regulates the actin 
cytoskeleton organization in vivo (63, 64).
Recently, elevated mTORC2 activity has been linked to certain types of
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tumors (65), making mTORC2 a target of cancer therapy (66, 67); however, 
mTORC2 specific inhibitors have not been successfully developed as yet.
Diverse roles o f mTORC1 and mTORC2 in d ifferent metabolic tissues
Two separate studies have showed that germline disruption of mTOR in 
mice leads to early embryonic lethality due to an impairment of proliferation in 
embryonic stem cells (68, 69). Conditional deletion studies were done afterward 
to understand the function of mTORC1 and mTORC2 in vivo.
Disruption of mTORC1 generally reduced S6K phosphorylation and 
resulted in smaller cells in the tissue. However the outcome and whole body 
phenotype of tissue specific mTORC1 disruption are distinct.
Deletion of raptor in mouse skeletal muscle leads to a progressive muscle 
dystrophy, impaired oxidative capacity of the muscle and eventually the death of 
the mice (70). Muscle deficient in raptor also exhibited increased glycogen 
storage, which was a result of elevated Akt phosphorylation due to lack of 
S6K1-IRS negative feedback signaling (70). Deletion of raptor in the liver results 
in a 40% reduction in liver weight, and a constant production of ketone bodies, 
which are generally produced under fasting conditions as an alternative energy 
source for other tissues (71). Deletion of raptor in adipocytes protects mice 
against diet-induced obesity and hypercholesterolemia by increasing 
mitochondrial uncoupling in adipocytes (72).
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Tissue-specific disruption of mTORC2 by rictor deletion generally causes 
mild effects, so those studies did not shed much light on understanding of 
mTORC2 itself in those tissues (50). For example, mice with rictor deletion in 
skeletal muscle appear normal (70), and mice with rictor deletion in adipose tissue 
appear bigger due to increased serum insulin and IGF1 levels, but the weight of 
adipose tissue was not changed (73). Skeletal muscle specific mTOR deletion 
phenocopies raptor deletion, indirectly suggesting that mTORC2 may play a minor 
role in skeletal muscle (74).
In the heart, mTORCI is required for Akt regulated cardiac hypertrophy; 
rapamycin treatment can fully block hypertrophy induced by overexpression of a 
constitutively active Akt (75). However, cardiac specific overexpression of a 
constitutively activated mTOR does not increase heart weight (76). By contrast, 
inducible deletion of mTOR in cardiomyocytes leads to heart failure due to 
inhibition of protein translation induced by constitutive dephosphorylation of 
4E-BP1 (77). Cardiac specific raptor deletion phenocopies cardiac specific mTOR 
deletion (78), again suggesting mTORC2 does not play an important role in the 
heart. Despite an indispensable role of mTOR in adult heart, mTOR seems absent 
in embryonic heart revealed by in situ hybridization in E9.5 mouse embryos (79), 
raising a question whether mTOR is required for cardiac development.
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mTOR and cardiac metabolism
The heart is a "metabolic omnivore” with the capacity to oxidize both fat 
and carbohydrates (glucose and lactate), but favoring fatty acid as the fuel for ATP 
generation (accounts for about 60-70% of ATP produced). The place for both 
glucose oxidation (GLOX) and fatty acid oxidation (FAO) is mitochondria, power 
plants for cells, which accounts for about 30% of cellular volume in the 
cardiomyocytes (80).
As previously described, mTOR regulates mitochondrial biogenesis 
through transcriptional regulation of PGC-1a and many other mitochondrial genes 
in skeletal muscle (47), but whether mTOR affects cardiac metabolism through 
the regulation of PGC-1a is not known.
Glucose utilization in the heart includes many steps: glucose uptake, 
phosphorylation, glycolysis and oxidation. During glycolysis, glucose is broken 
into two molecules of pyruvate which then enters mitochondria to be broken into 
acetyl-CoA and CO2, a process catalyzed by the enzyme pyruvate 
dehydrogenase (PDH). Then, acetyl-CoA enters the TCA cycle to generate NADH 
and FADH2 which are used by the electron transfer chain to transport protons to 
build up the gradient for ATP generation.
Fatty acid metabolism in the heart starts with the transport of fatty acids 
into cells through diffusion or via specific transporters such as the CD36 
transporter. Cytoplasmic fatty acid is then rapidly converted to FA-CoA, which
22
utilizes carnitine, through a reaction catalyzed by carnitine-palmitoyl transferase 
(CPT), to generate fatty acyl-carnitine, which can be directly transported into 
mitochondria. Once inside the mitochondria, fatty acyl-carnitine reacts 
with coenzyme A to generate fatty acylCoA (81). Fatty acids then undergo 
P-oxidation in the mitochondria to generate acetyl-CoA, which enters the TCA 
cycle similar to acetyl-CoA generated from pyruvate during glucose metabolism. 
CPT is believed to be the rate-limiting enzyme in fatty acid oxidation.
However, whether expression and enzymatic activity of key enzymes in 
glucose and fatty acid metabolism are regulated in the heart by mTOR has not 
been established.
Summary and rationale
In summary, cardiac insulin signaling is vital for the function of the heart 
and cardiac insulin resistance predisposes to heart disease, so understanding the 
mechanisms and consequences of cardiac insulin resistance is important for 
advancing development of therapeutics for heart disease.
In Chapter 2, to understand the mechanism of how elevated PI3K-Akt 
signaling in diabetic hearts impairs cardiac glucose uptake, we utilized two 
different mouse models overexpressing either a constitutively activated PI3K or 
myrAkt1 restricted to the cardiomyocytes to test whether activation of 
mTORC1-S6K-IRS negative feedback pathway desensitizes insulin signaling and
23
leads to reduced basal and insulin-stimulated glucose uptake.
Despite intensive studies on mTOR, little is known about the role of mTOR 
in regulation of cardiac mitochondrial function and energetics. With a cardiac 
specific inducible mTOR deletion model, we identified an impairment of fatty acid 
but not glucose utilization in mTOR deficient heart, and we are analyzing changes 
of key enzymes involved in both glucose and fatty acid metabolism and seeking to 




INCREASED CARDIAC PI3K-AKT SIGNALING IMPAIRS 
INSULIN-STIMULATED GLUCOSE UPTAKE VIA 
A MECHANISM INDEPENDENT OF MTORC1
Introduction
Regulation of glucose transport and utilization by insulin is central to the 
maintenance of glucose homeostasis (82). Insulin regulates glucose transport and 
utilization via a complex signaling cascade involving serial phosphorylation and 
activation of kinases such as PI3K and Akt. The binding of insulin to the 
extracellular domain of the insulin receptor (IR) leads to phosphorylation and a 
conformational change in its intracellular tyrosine kinase domain that allows the IR 
to serve as a signaling scaffold and docking site for many proteins including 
insulin receptor substrate (IRS) proteins (3). IRS proteins promote the assembly 
of regulatory and catalytic subunits of PI3K, which phosphorylates 
phosphatidylinositol 4,5-bisphosphate (PIP2) to generate phosphatidylinositol 
3,4,5 triphosphate (PIP3) (4). Production of PIP3 recruits PDK1 
(phosphoinositide-dependent kinase 1) to the plasma membrane for activation, 
which then phosphorylates Akt and other signaling intermediates (5). Activation of 
PI3K and Akt plays critical roles in the regulation of insulin stimulated glucose 
uptake by promoting translocation of GLUT4 glucose transporters.
In cardiomyocytes, the two most highly expressed glucose transporters are 
GLUT1 and GLUT4, with GLUT4 being most abundant. GLUT1 mediates basal 
glucose transport, while GLUT4 is mainly responsible for insulin, or 
contraction-mediated glucose transport (83). In quiescent myocytes, the majority 
of GLUT4 protein resides in a specialized vesicle population in an intracellular
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compartment. Upon insulin stimulation, GLUT4 vesicles are translocated to the 
plasma membrane (PM) via a multiple-step process by which GLUT4 storage 
vesicles (GSVs) move to the PM, tether, dock and ultimately fuse with the PM to 
expose GLUT4 proteins on cell surface, and this process involves modulation of 
cortical F-Actin networks, snare proteins and small GTPases of the Rab family 
(84). In addition to activation of PI3K and Akt, insulin regulates GLUT4 trafficking 
at multiple levels, such as phosphorylation of the Rab-GAP AS160, which 
activates a family of small G proteins (Rabs) to promote movement of GSVs to the 
PM (85). At the PM, insulin activates PI3K and RalA, to promote tethering and 
docking of GSVs to an actin filament network (86). Insulin also activates Rac1 
protein to promote actin remodeling that facilitates the GSV docking process (87). 
The rate of final GSV and PM fusion depends on physical properties of the PM 
and also requires activation of PKCZ, both of which are regulated by insulin (88). 
In cardiomyocytes, an additional Ca2+ signal activates Akt to promote GLUT4 
translocation (89).
Insulin stimulated glucose transport is an important rate-limiting step for 
glucose metabolism in adipose tissue, cardiac and skeletal muscle and this 
fundamental process is severely disrupted in type II diabetes and other insulin 
resistant states (90). However, the mechanisms that lead to the development of 
insulin resistance and reduced insulin stimulated glucose transport remains 
incompletely understood, particularly in the heart. Chronic insulin exposure
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desensitizes insulin signaling in many cell types and tissues. For example, in L6 
myoblasts, chronic insulin treatment decreased Akt and MAPK phosphorylation 
and glucose uptake in response to subsequent insulin stimulation, via a 
mechanism involving reduced content of IRS1 and IRS2 proteins. Inhibition of 
PI3K by LY294002 restored IRS1 and IRS2 protein content and increased the 
responsiveness of Akt and MAPK towards subsequent insulin stimulation (91). 
Loss of function of the TSC1-TSC2 complex leads to constitutive, unrestrained 
Rheb-mTORC1-S6K1 signaling. In TSC1-/- or TSC2-/- mouse embryonic 
fibroblasts (MEFs) there was a reduction of IRS1 and IRS2 proteins, which 
resulted in a decrease of insulin signaling (92). Furthermore, deletion of S6K 
protected mice from age- and diet-induced obesity and enhanced insulin 
sensitivity (13). Thus an mTORC1-S6K1-IRS negative feedback pathway 
activated by abnormal PI3K-Akt activity may lead to insulin resistance.
In diabetic patients, basal and insulin stimulated cardiac glucose transport 
is reduced (9, 10), but PI3K-Akt signaling is increased (10). Whether elevated 
PI3K-Akt signaling activates this mTORC1-S6K1-IRS negative feedback pathway 
in the heart leading to reduced glucose uptake in not known. This report sought to 
understand the mechanism by which activation of PI3K-Akt signaling in the heart 
may modulate cardiac glucose uptake in two mouse models overexpressing either 
a constitutively activated PI3K or a myristoylated Akt1. We also tested whether 
the mTORC1 inhibitor rapamycin could restore the insulin stimulated glucose
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transport in these hearts. Our study reveals that activation of PI3K and Akt in the 
heart impairs glucose uptake despite intact GLUT4 translocation by mechanisms 
that are independent of mTORC1 activation.
Materials and methods
Animals and rapamycin administration
Constitutively active PI3K (caPI3K) transgenic mice were previously 
generated by Dr. Seigo Izumo (93) by expressing a chimeric protein that contains 
the iSH2 domain of p85 fused to the N-terminus of bovine p110a driven by the 
aMHC promoter. The caPI3K mice are on a pure FVB background.
MyrAkt1 mice were previously generated by Dr. Kenneth Walsh (75). 
MyrAkt1 mice have two transgenes: tTA driven by aMHC and a myrAkt1 
transgene under the TetO promoter. MyrAkt1 mice were fed DOX chow (1g/kg) 
until the predetermined time (8 weeks old) for myrAkt1 transgene induction. 
MyrAkt1 mice are on mixed background.
MyrAkt1 mice were mated to mice hosting a c-myc GLUT4 construct (94) 
driven by ‘tet’O promoter to generate cardiac specific myrAkt1 and c-myc GLUT4 
co-expression mice (triple transgenic mice).
Rapamycin at 2 mg/kg/day was administered by intraperitoneal injection 
(i.p.). The solvent for rapamycin is 0.2% sodium carboxymethyl cellulose, 0.25% 
tween 80 and 2% dimethyl sulfoxide (DMSO) in water.
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All animals described in this report were maintained and used 
in accordance with protocols approved by the Institutional Animal Care and Use 
Committee of the University of Utah.
Immunoprecipitation and western blotting
Mice were fasted for 6 hours before they were anesthetized with chloral 
hydrate (1mg/g body weight) by i.p. injection. For insulin stimulation, human 
insulin (0.1U/30g body weight) was injected through the inferior vena cava after 
anesthesia. Heart muscle was dissected and immediately frozen in liquid nitrogen 
after 5 minutes of insulin stimulation.
Proteins were extracted from heart tissue with homogenization buffer 
containing 0.1% Triton X-100 with a protease and phosphatase inhibitor cocktail 
(Pierce, Rockford, IL). Protein concentration was then determined by Micro BCA 
Protein Assay kit (Pierce, Rockford, IL).
For IRS1 Immunoprecipitation, 0.5 mg of heart lysates were incubated with 
rabbit polyclonal antibodies against IRS1 for 3 hours at 4°C on a rocker. Then 
protein A-Sepharose was added and incubated for 1 hour at 4°C with gentle 
rocking. After being washed three times with buffer, the immunocomplexes were 
dissociated by boiling with 2X Novex Tris-glycine SDS sample loading buffer 
(Invitrogen, Carlsbad, CA) at 95°C for 5 minutes.
For western blotting, 20-100ug protein were loaded and resolved by
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sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to PVDF (low fluorescence) or nitrocellulose membrane for 
immunoblot detection with specific antibodies. Detection was performed by 
measuring intensity of fluorescence from secondary antibodies using the Odyssey 
Infrared Imaging System and quantification was done with their accompanying 
software (version 3.0; LI-COR Biosciences, Lincoln, NE).
Primary antibody list: Actin and Tubulin antibodies were purchased from 
Sigma (St. Louis, MO), IRS1 and IRS2 antibodies were purchased from Upstate 
(Now Millipore, Billerica, MA), phospho-tyrosine, R  antibody, pIRSI Ser312 
antibodies were purchased from Santa Cruz (Santa Cruz, CA), all other 
antibodies were purchased from Cell signaling (Danvers, MA).
Secondary antibody list: goat anti-rabbit 800 and goat anti-mouse 800 
were purchased from Li-Cor (Lincoln, NE). Alexa 488, Alexa 597, Alexa 680 
antibodies were purchased from Invitrogen (Carlsbad, CA).
Cardiomyocyte isolation
Mice were anesthetized and heparinized, then the hearts were cannulated 
and perfused with buffer containing 16 U/ml type IV collagenase for 10-12 min. 
The heart was then minced and myocytes were dissociated by gentle pipetting. 




Insulin-stimulated 2-DG uptake assays were performed in triplicate in 
12-well culture plates as described before (95). In brief, isolated cardiomyocytes 
were attached to laminin-coated plates. Attached cardiomyocytes were then 
conditioned in modified Dulbecco’s modified Eagle’s (DMEM) low glucose 
medium for 30 minutes before being fasted for 40 minutes in DMEM no glucose 
medium supplemented with 1mg/ml BSA and 1 mM pyruvate. Glucose uptake 
was performed by adding 2-[1,2-3H]-deoxy-D-glucose in the presence of 0, 0.1, 
1,10 nM insulin. The data is presented by quantifying the radioactivity of
2-[1,2-3H]-deoxy-D-glucose.
C-myc GLUT4 staining in nonpermeabilized cardiomyocytes
Cardiomyocytes were isolated and attached to laminin coated chamber 
slides. Attached cells were conditioned and fasted as described for 2-DG uptake, 
and then they were treated with 10 nM insulin or saline for 15 min before being 
fixed with cold 4% paraformaldehyde (PFA) in PBS. Fixed cells were washed and 
incubated with 100 mM glycine for 10 min. Then cells were blocked with 5% BSA 
in PBS for 15 min on ice followed by overnight incubation with primary antibody in 
a moist box at 4°C. The next day, cells were washed 3 times with PBS and then 
incubated with secondary antibody for 1 hour at room temperature. Then cells 
were washed again three times with PBS and mounted with Prolong Gold
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Antifade/DAPI reagent (Invitrogen, Carlsbad, CA). The slides were imaged with 
an Olympus FV1000 confocal microscope.
Statistical analysis
All values are shown as mean ± standard error. Data sets with two groups 
were compared with Unpaired Student’s t test. Data sets with more than two 
groups were examined by one-way ANOVA followed by Bonferroni’s multiple 
comparison test as a post-hoc test. A P<0.05 was considered significant. T test 
was performed using Microsoft EXCEL; ANOVA tests were performed using 
GraphPad Prism. Plots were drawn using GraphPad Prism.
Results
Expression of myrAkt1 impairs insulin stimulated 2-DG 
uptake in isolated cardiomyocytes 
Inducible Akt activation in the heart was achieved in transgenic mice 
expressing a myristolated Akt1 transgene fused to a ‘tet’O operator sequence 
which is governed by cardiomyocyte-restricted expression of a tetracycline 
transactivator (tTA) protein (Tet-Off) (96). In the absence of doxycycline (DOX, a 
more stable tetracycline analogue), tTA binds to ‘tet’O operator and induces target 
gene expression, which will normally be suppressed in the presence of DOX. 10 
days after replacing DOX chow with normal chow, Akt Ser473 and Thr308
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phosphorylation increased by 29.2% and 36.3% respectively in myrAkt1 hearts. 
Administration of insulin via the inferior vena cava, markedly increased Akt 
Ser473 and Thr308 phosphorylation (> 30-fold) in both wild type (WT) and 
myrAkt1 hearts, and there was no difference in maximal insulin-stimulated Akt 
phosphorylation between WT and myrAkt1 groups (Fig 2-1A). Basal S6 
phosphorylation on Ser235/236 was also increased (Fig 2-1A). Consistent with 
the increase in basal Akt phosphorylation, heart weight was increased by 8.7% 
when normalized to body weight and was further increased by 11.4% after 2-week 
withdrawal from DOX (data not shown). MyrAkt1 mice maintained on DOX chow 
exhibited basal levels of Akt Ser473 phosphorylation that were comparable to wild 
type (WT) mice, indicating the absence of leaky transgene expression (97) (data 
not shown).
Despite a constitutive increase in the activation of the mTORC1 target S6 
in myrAkt1 hearts, the ability of insulin to increase tyrosine phosphorylation of 
IRS1 protein was normal in myrAkt1 hearts (Fig 2-1B). Furthermore, IRS1 serine 
phosphorylation at multiples sites including the S6K1 target site Ser1101 (11) was 
not increased in myrAkt1 hearts (Fig 2-1C), suggesting the mTORC1-S6K1-IRS 
negative feedback pathway was not activated by the level of transgene activation 
achieved after 10 days of DOX withdrawal. Also, IRS1 and IRS2 protein levels 
were maintained in these myrAkt1 hearts (Fig 2-2). Acute insulin exposure did not 
increase IRS1 serine phosphorylation, which is consistent with the notion that IRS
34
35
Figure 2-1: Overexpression of myrAkt1 in the heart. A. Basal and 
insulin-stimulated Akt Ser473 and Thr308 phosphorylation and S6 Ser235/236 
phosphorylation in myrAkt1 hearts following 10-day withdrawal of DOX. B. 
Insulin-stimulated tyrosine phosphorylation of IRS1 protein in myrAtk1 hearts. 
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Figure 2-2: IRS1 and IRS2 protein expression and phosphorylation levels of IRS1 
in WT and myrAkt1 hearts.
serine phosphorylation is a slow process compared to IRS1 tyrosine 
phosphorylation (Fig 2-2).
Despite a modest increase in basal Akt phosphorylation, basal glucose 
uptake was not increased in cardiomyocytes isolated from myrAkt1 hearts. 
Remarkably, and despite robust activation of Akt phosphorylation by insulin, 
insulin-stimulated 2-deoxyglucose (2-DG) uptake was blunted in myrAkt1 
cardiomyocytes. Relative to identically treated WT cardiomyocytes, 2-DG uptake 
was reduced by 80% in myrAkt1 cardiomyocytes following stimulation with 10 nM 
insulin (Fig 2-3). It is well established that acute activation of Akt will stimulate 
GLUT4 translocation and increase glucose uptake (98). However the gradual 
decline in systemic levels of DOX by chow removal may render it difficult to detect 
an early increase in basal glucose transport in our mouse model. Taken together, 
these data suggest that moderate and short-term activation of Akt1 impairs insulin 
stimulated 2-DG uptake by a mechanism that may be independent of 
mTORC1-S6K1 inhibitory feedback signaling to IRS proteins.
Expression of a constitutively activated PI3K impairs 
insulin stimulated 2-DG uptake 
We next examined an alternative mouse model with cardiac restricted 
expression of a constitutively activated PI3K (caPI3K). CaPI3K mice had a 26% 





























Figure 2-3: Insulin stimulated 2-DG uptake in isolated myrAkt1 cardiomyocytes. 
n=4-5. *: p<0.05, **: p<0.01.
Similar to myrAkt1 hearts, basal Akt phosphorylation on Ser473 and Thr308 sites 
in caPI3K hearts was increased by 4.4’ and 3.3-fold respectively, and was further 
increased following in vivo insulin administration to a level comparable to that of 
insulin-stimulated WT hearts (Fig 2-4). Basal S6K1 and S6 phosphorylation was 
also increased by 146.0% and 65.8% respectively, but insulin further stimulated 
S6K1 in myrAkt1 hearts to levels that were equivalent to that of similarly treated 
WT hearts. Basal Gsk3p phosphorylation was not increased in caPI3K hearts, but 
was stimulated by insulin (Fig 2-5).
In 5-week-old caPI3K hearts, the content of IRS1 and IRS2 proteins was 
unchanged (Fig 2-6). However, despite an increase in basal PI3K-Akt signaling 
and a further increase in the phosphorylation of Akt and its downstream targets 
following insulin stimulation, cardiomyocytes isolated from 5-week old caPI3K 
mice did not exhibit increased basal 2-DG uptake and insulin stimulated 2-DG 
uptake was blunted. Relative to identically treated WT cardiomyocytes, 2-DG 
uptake was reduced by 47.5% in caPI3K cardiomyocytes following stimulation 
with 10 nM insulin (Fig 2-7). Thus activation of PI3K in the heart also impairs 
insulin stimulated 2-DG uptake via mechanisms that may be independent of 
mTORC1-S6K1 inhibitory feedback signaling to IRS proteins.
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Figure 2-4: Basal and insulin-stimulated Akt phosphorylation on Ser473 and 
Thr308 sites in caPI3K hearts. Upper panel: western blots; lower panel: 
quantificiation. *: p<0.05, **: p<0.01.
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Figure 2-5: Basal and insulin-stimulated phosphorylation of Akt downstream 
targets. *: p<0.05, **: p<0.01.
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Figure 2-6: IRS1 and IRS2 protein levels in 5-week-old caPI3K hearts. 



























Figure 2-7: Insulin stimulated 2-DG uptake in isolated caPI3K cardiomyocytes. 
n=5. *: p<0.05.
Prolonged myrAkt1 expression decreases IRS2 protein, rapamycin treatment 
normalizes IRS2 protein content but fails to restore insulin stimulated 2-DG 
uptake in myrAkt1 cardiomyocytes
The data presented thus far suggest that short-term activation of PI3K or 
Akt in the heart desensitizes insulin-mediated glucose uptake independently of 
inhibitory feedback by mTORC1-S6K1 to IRS proteins. To explore if longer-term 
activation of this signaling pathway will eventually reduce IRS signaling, we 
examined 8-week-old caPI3K mice and observed 48.8% and 48.6% reduction in 
IRS1 and IRS2 proteins, respectively (Fig 2-8A), and the ability of insulin to 
increase Akt phosphorylation was blunted (Fig 2-8B). Similar changes were 
observed in mice in which the myrAkt1 transgene was activated for 14 days, in 
that IRS2 protein was reduced by 68% although, IRS1 protein levels were not 
changed (Fig 2-8C). Treatment of 2-week induced myrAkt1 mice with rapamycin 
normalized IRS2 protein content (Fig 2-8C). Thus, longer-term activation of PI3K 
and Akt will eventually reduce IRS signaling in the heart in an 
mTORC1-dependent manner.
Given our earlier findings that Akt activation impaired glucose uptake prior 
to any reduction in IRS proteins, we reasoned that restoration of IRS proteins with 
rapamycin treatment would not restore insulin-mediated glucose uptake in mice 
with longer-term activation of Akt. As shown in Figure 3-5A, rapamycin completely 
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Figure 2-8: Chronic PI3K-Akt activation reduces IRS protein through a 
mechanism involving mTORC1. A. IRS1 and IRS2 protein levels in 8-week-old 
caPI3K hearts. B. Insulin stimulated Akt phosphorylation in 8-week-old caPI3K 
hearts. C. 14 days induction of myrAkt1 reduces IRS2 protein level, which was 
normalized by rapamycin treatment. Quantification is shown below the blots. *: 
p<0.05, **: p<0.01.
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Figure 2-9: The effect of rapamycin treatment on basal and insulin-stimulated 
phosphorylation of Akt and its downstream kinases in myrAkt1 hearts following 
14-day of DOX withdrawal.
decreased Akt Ser473 phosphorylation via inhibition of mTORC2, a kinase 
complex that directly phosphorylates Akt on Ser473 (53) (Fig 2-9). Although 
attenuated, insulin increased Akt Thr308 phosphorylation in WT hearts treated 
with rapamycin, and to a lesser extent in rapamycin-treated myrAkt1 hearts. A 
similar pattern was observed with Gsk3p phosphorylation (Fig 2-9). Rapamycin 
treatment did not inhibit insulin-stimulated glucose transport in WT 
cardiomyocytes, but failed to restore insulin-mediated glucose transport in 
myrAkt1 cardiomyocytes (Fig 2-10). Moreover, treatment of 5-week-old caPI3K 
mice or myrAkt1 mice following 10 days of DOX withdrawal with rapamycin also 
abolished the increase in S6 phosphorylation, but did not restore glucose uptake 
(data not shown). Thus inhibition of mTOR signaling in mice with constitutive 
activation of PI3K or Akt does not restore insulin-mediated glucose transport. 
Although the inhibitory impact of rapamycin on insulin-mediated Akt signaling 
could be a basis for the lack of rescue with rapamycin, the fact that rapamycin 
does not impair glucose transport in WT mice makes this possibility less likely. 
Taken together, these findings support the hypothesis that chronic Akt activation 
may inhibit glucose uptake via mTOR-independent mechanisms.
Impairment of 2-DG uptake in myrAkt1 cardiomyocytes occurs 
despite normal GLUT4 translocation 




























Figure 2-10: The effect of rapamycin treatment on insulin-stimulated 2-DG uptake 
in WT and myrAkt1 cardiomyocytes. n=4-8, *: p<0.05 vs. WT Vehicle (Vehi).
Decreased 2-DG uptake could be a result of a reduction in GLUT1 or GLUT4 
proteins. Expression of myrAkt1 reduced GLUT4 protein by 16%, while GLUT1 
expression was increased by 62% following 10 days of DOX withdrawal (Fig 2-11). 
Those effects seem, at least in part, to be regulated at transcriptional levels as 
evidenced by a 2-fold rise in GLUT1 mRNA and a 40% drop in GLUT4 mRNA in a 
microarray (data not shown). However, a 16% reduction of GLUT4 protein cannot 
account for an 80% reduction of maximal insulin stimulated 2-DG uptake. Also, 
rapamycin treatment restored the GLUT4 content (Fig 2-11) but failed to restore 
insulin stimulated 2-DG uptake, confirming that the change of GLUT4 protein 
cannot account for impaired 2-DG uptake in myrAkt1 cardiomyocytes.
Meanwhile, phosphorylation of AS160 was also increased in myrAkt1 
hearts (Fig 2-12), implying that GSV translocation might not be impaired by 
myrAkt1 expression. To determine whether GLUT4 protein was normally 
translocated and inserted into the plasma membrane, immunofluorescence 
detection of c-myc GLUT4 in nonpermeabilized cardiomyocytes was used. For 
these studies, transgenic mice that harbor a doxycycline-regulated c-myc GLUT4 
fusion transgene in which c-myc is fused to the exofacial loop of GLUT4 (94) were 
generated. c-myc GLUT4 mice were crossed to myrAkt1 double transgenic mice 
to generate inducible myrAkt1 and c-myc GLUT4 co-expressing mice (triple 
transgenic mice). In the absence of insulin stimulation, negligible levels of c-myc 
GLUT4 fluorescence were detected in nonperm eabilized c-m yc GLUT4
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Figure 2-11: GLUT1 and GLUT4 protein levels in WT and myrAkt1 hearts in the 
presence/absence of rapamycin treatment. Quantification is shown below the
blots.
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Figure 2-12: Insulin stimulated AS160 phosphorylation in WT and myrAkt1 hearts. 
Quantification is shown below. *: p<0.05; **: p<0.01.
cardiomyocytes. After stimulation with 10 nM insulin, the c-myc GLUT4 
fluorescence was greatly increased, confirming insulin stimulated GLUT4 
translocation in WT cardiomyocytes. Overexpression of myrAkt1 in 
cardiomyocytes increased c-myc GLUT4 fluorescence even in the absence of 
insulin, indicating overexpression of myrAkt1 was sufficient to target GLUT4 
protein to cell surface; the intensity of fluorescence could not be further increased 
following insulin stimulation (Fig 2-13). Taken together with the observation that 
basal 2-DG glucose uptake is not increased in myrAkt1 cardiomyocytes, the 
increase of basal c-myc fluorescence suggests that GLUT4 intrinsic activity is 
significantly impaired in myrAkt1 cardiomyocytes.
Discussion
There is an emerging consensus that many pathways conspire to induce 
insulin resistance in muscle and adipose tissue. Although impaired 
insulin-stimulated glucose uptake is a consistent feature, this may occur in the 
absence of a coordinate reduction in insulin-mediated IRS1 phosphorylation or 
Akt activation (99). Recent studies in cardiac muscle have also suggested that in 
models of insulin resistance, persistent activation of Akt signaling remains, 
despite a reduction in glucose uptake (10). In some of these studies the 
impairment in glucose uptake was attributed to defects in GLUT4 translocation or 
to a reduction in GLUT4 protein or both, via mechanisms that are incompletely
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Figure 2-13: C-myc immunofluorescence staining in nonpermeabilized c-myc 
GLUT4 and myrAkt1 co-expressed cardiomyocytes. C-myc immunofluorescence 
staining in nonpermeabilized cardiomyocytes from c-myc GLUT4 heart (control) 
and c-myc GLUT4/myrAkt1 co-expression heart (Triple Transgenic) treated with 
saline or insulin for 15 minutes. Scale bar: 10 ^m.
understood (10, 100). Given that persistent activation of PI3K and Akt in the heart 
may be a consequence of hyperinsulinemia in insulin resistant states, the present 
study was designed to determine if constitutive activation of PI3K and Akt 
signaling in the heart could independently impair insulin-mediated glucose uptake 
and GLUT4 translocation. The study was predicated on the hypothesis that 
chronic activation of PI3K and Akt signaling would desensitize insulin-mediated 
glucose transport via mechanisms that were secondary to mTORCI-mediated 
activation of S6K, which would desensitize IRS signaling via serine 
phosphorylation of IRS proteins and IRS protein degradation. Unexpectedly, the 
present study indicates that in cardiomyocytes, PI3K activation may impair 
myocardial glucose uptake prior to any evidence of S6K activation. Moreover, the 
defect in glucose uptake occurs despite normal translocation of GLUT4. These 
data indicate that chronic activation of PI3K may impair glucose uptake via 
mechanisms that may impair the intrinsic activity of the GLUT4 transporter.
The study examined two independent models of chronic activation of the 
PI3K-Akt signaling pathway in cardiomyocytes. The first model of inducible Akt 
activation was reported to cause significant cardiac hypertrophy following > 2 
weeks of DOX withdrawal (75). Cardiac function was initially preserved in these 
mice, although persistent transgene activation for > 4 weeks ultimately led to 
heart failure. We chose to examine these animals at the earliest time point at 
which we could detect activation of Akt, namely at 10 days following DOX
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withdrawal and at a time point when cardiac hypertrophy was minimal. At this time 
point, there was approximately a 30% increase in Akt phosphorylation that was 
substantially lower than maximal insulin-stimulated Akt phosphorylation. Although 
S6 phosphorylation was increased by 3-fold, we observed no increase in serine 
phosphorylation of IRS proteins nor was there any impairment in the ability of 
insulin to phosphorylate IRS1 or to fully activate Akt. Despite this, 
insulin-mediated glucose uptake was significantly repressed. The second model 
of constitutive PI3K activation (caPI3k) does not develop ventricular dysfunction. 
In 5-week-old caPI3K mice we also observed normal levels of IRS proteins, and a 
preserved ability of insulin to activate Akt and its downstream target GSK3p. As 
was the case in the inducible Akt model, insulin-stimulated glucose uptake was 
significantly impaired. These observations suggested that persistent activation of 
Akt rapidly desensitizes glucose uptake, despite preserved proximal insulin 
signaling.
To evaluate the possibility that impaired glucose uptake could be a 
consequence of a defect in GLUT4 translocation, we utilized a myc-epitope 
tagged GLUT4 construct, in which myc is inserted in the exofacial loop of GLUT4. 
Upon plasma membrane insertion of this transgene, the myc epitope is exposed 
to the extracellular space. Detection of myc by immunofluorescence in 
non-permeabilized cells is a widely accepted indicator of insertion of GLUT4 into 
the plasma membrane. We therefore developed mice in which both myc-GLUT4
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and Akt could be simultaneously induced. Activation of Akt was associated with 
phosphorylation of AS160 and clear evidence of gain in surface GLUT4 in the 
absence of insulin, to a level equivalent to that observed in insulin-stimulated 
control cells. Treatment with insulin did not further increase surface GLUT4. Yet 
despite clear evidence of Akt-mediated GLUT4 translocation, we obtained no 
evidence for augmented basal or insulin-stimulated glucose uptake. These 
observations support the hypothesis that constitutive activation of Akt in 
cardiomyocytes may impair glucose uptake at a post-insertion step. Although 
much progress has been made in elucidating many of the signaling pathways 
activated by insulin that mediate GLUT4 translocation and the molecular 
mechanisms governing docking and fusion of GLUT4 containing vesicles (101), 
far less is known about the regulation of the specific activity of GLUT4 after its 
insertion into the plasma membrane. Prior studies in cultured adipocytes and 
muscle cells suggested that activation of GLUT4 may play an important role in 
glucose transport after transporter insertion (102, 103). Interestingly, although 
direct delivery of PIP3 to adipocytes promoted GLUT4 translocation in cultured 
adipocytes and L6 myocytes, there was no associated increase in glucose uptake, 
suggesting a vital role of posttranslocational activiation of GLUT4 in glucose 
uptake (104). The present study shows for the first time in vivo, that although 
persistent activation of PI3K and Akt may lead to insertion of GLUT4 into the 
sarcolemmal membrane of cardiomyocytes, GLUT4 activation is desensitized. In
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addition to translocation, insulin also regulates the post-fusion dispersal and 
spatial distribution of GLUT4 in the plasma membrane, which may correlate with 
the full activation of glucose uptake (105). Whether chronic activation of Akt1 in 
the heart leads to a defect of GLUT4 dispersion needs to be further studied.
Our study revealed that constitutive activation of PI3K and Akt led to 
activation of the mTORC1 target S6K, which has been shown in many studies to 
impair insulin signal transduction via a feedback inhibition mechanism involving 
serine phosphorylation of IRS1 and its subsequent proteasomal degradation (106, 
107). With relatively short-term activation of PI3K or Akt we obtained no evidence 
that this pathway was being activated in the heart at a time when glucose uptake 
was impaired. However, with longer-term PI3K activation in 8-week-old mice, 
there was clear evidence of reduced IRS1 and IRS2 protein and impaired insulin 
stimulation of Akt. With > 14 days of DOX withdrawal in inducible myrAkt1 
transgenic mice, there was a reduction in IRS2 protein, and treatment of myrAkt1 
mice with rapamycin returned IRS2 protein to WT levels, but did not restore 
insulin-mediated glucose uptake. Although insulin stimulated phosphorylation of 
Akt on Ser 473 was abolished by rapamycin, likely as a result of impairment of 
mTORC2, rapamycin treatment did not impair insulin stimulated glucose uptake in 
WT mice. We also treated myrAkt1 transgenic mice following 10-day DOX 
withdrawal with rapamycin to inhibit mTORC1 signaling even though we saw no 
evidence at this stage of impaired insulin signaling to IRS proteins, and again we
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were unable to restore insulin-mediated glucose uptake. Thus, the inability of 
rapamycin treatment to restore insulin-mediated glucose uptake in mice with 
constitutive expression of myrAkt1 supports the hypothesis that the defect in 
glucose uptake is not mediated by mTORC1-S6K-IRS feedback inhibition.
In conclusion, the present study sheds additional mechanistic insight into 
the rapid impairment of insulin-mediated myocardial glucose uptake that 
characterizes insulin resistant states. Using models of constitutive activation of 
PI3K and Akt signaling pathways, which mimic the impact of diabetes and obesity 
on myocardial insulin signaling, we show that Akt activation impairs glucose 
uptake via mechanisms that impair the activation of GLUT4 transporters.
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CHAPTER 3
DELETION OF MTOR IN ADULT MURINE HEART REDUCES 
FATTY ACID UTILIZATION, ATP PRODUCTION AND 
LEADS TO HEART FAILURE INDEPENDENTLY 
OF REGULATION OF PGC-1A
Introduction
Mechanistic target of rapamycin (mTOR) is an essential gene in mice (68, 
69). mTOR engages in two distinct complexes mTORC1 and mTORC2, 
distinguished by their specific binding partners raptor and rictor respectively (108). 
Disruption of mTOR affects both complexes; however, disruption of mTORC2 by 
rictor deletion in metabolic tissues generally has mild effects (50, 70, 73).
mTOR is also required for murine heart development, growth and function 
(109). An elegant study using a-MHC-mutated estrogen receptor-Cre-mutated 
estrogen receptor (shortened for MCM) (110) transgene to temporally control 
mTOR gene deletion by tamoxifen administration revealed that lack of mTOR in 
the adult heart leads to the heart failure and death of the mice 7 weeks after first 
tamoxifen administration, characterized by uncontrolled apoptosis, excess 
autophagy and altered mitochondrial structure (109). It was proposed that 
mechanistically, elevated 4E-BP1 protein, particularly nonphosphorylated 4E-BP1 
repressed protein translation in mTOR deficient hearts, leading to heart failure. 
Crossing MCM-mTOR mice to whole body 4E-BP1 deficient mice doubled median 
survival duration from 7 weeks to 14 weeks; however, a full rescue was not 
achieved, raising the possibility of additional mechanisms.
Disruption of mTORC1 by raptor deletion phenocopies mTOR deletion in 
the heart (78), supporting the concept that mTORC2 may play a less significant 
role. This study showed that mTORC1 is required for the adaptive hypertrophy
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after transverse aortic constriction through regulation of 4E-BP1 and S6K 
phosphorylation without changing total protein content. A switch of cardiac 
substrate oxidation from fatty acid to glucose in the hearts of raptor deficient mice 
was observed. However, these measurements were performed 4 weeks after 
gene deletion, but cardiac function was mentioned maintained up to 3 weeks after 
gene deletion. A switch of substrate metabolism in a failing heart from fatty acid to 
glucose is well described (111-114); thus the possibility remains that substrate 
switching in mTORC1 deficient hearts could be secondary to cardiac dysfunction.
The difference in nonphosphorylated 4E-BP1 protein content in two 
aforementioned studies might indicate mTORC2 specific regulation of total 
4E-BP1 protein content in the heart. But an interesting phenomenon is that an 
increase of nonphosphorylated 4E-BP1 has also been seen during transverse 
aortic constriction induced heart failure (109, 115), raising the possibility that 
inhibition of protein synthesis by increasing 4E-BP1 could be a secondary effect 
occurring during late stage heart failure, rather than being the sole or specific 
basis for heart failure following mTOR deletion in the heart.
mTORC1 has been shown to regulate mitochondrial biogenesis and 
oxidation through transcriptional regulation of PGC-1a in skeletal muscle and 
C2C12 cells (a skeletal muscle-derived cell line) via a complex involving mTOR 
and YY1 (47). In cardiac muscle, a role for this signaling mechanism has not been 
rigorously examined, nor has the impact of mTOR on mitochondrial bioenergetics.
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For these reasons, we used a doxycycline inducible TetO Cre governed by 
cardiac restricted expression of rtTA protein to achieve temporally controlled 
mTOR deletion in adult heart. Doxycycline, used for TetO induction, is less toxic 
than tamoxifen, which has been shown having a cardiotoxicity that can lead to 
severe transient dilated cardiomyopathy in mice (116). Also, to focus on the 
primary effects of mTOR deletion in the heart and potential mechanism by which 
lack of mTOR may lead to heart failure, we characterized myocardial substrate 
utilization, mitochondrial function and levels of proteins and genes that regulate 




Inducible and cardiac specific mTOR deficient mice (mTOR KO) were 
generated by developing compound transgenic mice harboring a reverse 
TetO-Cre construct (Jackson lab, strain number 6234), a reverse tetracycline 
transactivator (rtTA) under the control of the a-MHC promoter and floxed mTOR 
alleles (TetO-cretg/+/a-MHC-rtTAtg/+/mTORfl/fl). To induce TetO-Cre expression, 
mTOR KO mice were administered doxcycline hyclate (DOX) (Sigma, St. Louis, 
MO) at a dose of 4mg/kg body weight by intraperitoneal (i.p.) injection at 8 weeks 
of age, and then were kept on doxcycline chow (1g/kg) for 1 week, after which
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they were switched back to normal rodent chow for 3 more weeks to allow 
doxycycline washout before they were sacrificed for experiments. Expression of 
TetO-Cre results in recombination of the floxed mTOR alleles and deletion of the 
mTOR gene. mTORfl/fl mice were used as controls for mTOR KO mice.
All animal procedures in this study were approved by The Institutional 
Animal Care and Use Committee (IACUC) at the University of Utah.
Tissue harvesting and western blotting
Cytosolic proteins were extracted from whole heart lysates with 
homogenization buffer containing 0.1% Triton X-100. Protein concentration was 
determined by the Micro BCA Protein Assay kit (Pierce, Rockford, IL). Protein 
samples were mixed with 2X Tris-Glycine SDS sample buffer (Invitrogen, 
Carlsbad, CA) containing 5% p-mecapto-ethanol and boiled at 95 degree celsius 
for 10 minutes. Identical amounts of protein in equivalent volumes were loaded 
and resolved by SDS-PAGE and transferred to either PVDF (low fluorescence) or 
nitrocellulose membrane for immunoblotting detection with specific antibodies. 
Detection and quantification were performed by measuring the intensity of 
fluorescence from secondary antibodies using the Odyssey Infrared Imaging 
System and accompanying software (LI-COR Biosciences, Lincoln, NE).
Primary antibody list: LC3, Actin, and Tubulin antibodies were purchased 
from Sigma (St. Louis, MO); PDK1 antibody was purchased from Stressgen
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(Germany); VDAC antibody was purchased from MBL (Woburn, MA); 4-HNE, 
4E-BP1, CPT1a, PDH and PDK4 antibodies were purchased from Abcam 
(Cambridge, MA); PDK2, PDK3 and phospho-PDH (ser293) antibodies were 
purchased from Santa Cruz (Santa Cruz, CA); GLUT1 and GLUT4 antibodies 
were purchased from Millipore (Billerica, MA); all mitochondrial OXPHOS 
antibodies were purchased from molecular probes (now part of Invitrogen, 
Carlsbad, CA); and all other antibodies were purchased from Cell Signaling 
(Danvers, MA). Primary antibodies were used at recommended dilutions.
Fluorophore-conjugated secondary antibody list: goat anti-rabbit Alexa 680, 
goat anti-mouse Alexa 680, donkey anti-rabbit Alexa 680 and donkey anti-goat 
Alexa 680 antibodies were purchased from Invitrogen (Carlsbad, CA); goat 
anti-rabbit IRDye 800 and goat anti-mouse IRDye 800 were purchased from 
Li-Cor (Lincoln, NE). Secondary antibodies were used at 1:10,000 dilution.
RNA extraction, cDNA synthesis and quantitative real-time PCR
RNA extraction was performed using TRIzol (Life Technologies, Grand 
Island, NY) with manufacturer’s protocols, and cDNA synthsis was done using the 
Superscript III cDNA synthesis kit (Life Technologies, Grand Island, NY) with 
manufacturer’s protocols. Transcript levels of genes analyzed in this report were 
quantified by quantitative cyber green real-time PCR and expressed as fold 
change compared to controls. Primers of genes were designed using NCBI
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Primer Blast. Ribosomal protein 16S (rp16S) gene was used as internal 
reference.
Hyperinsulinemic euglycemic clamp
Hyperinsulinemic euglycemic clamps were performed in nonsedated mice 
as previously described with minor changes (117). In summary, the mouse jugular 
vein was catheterized under avertin anesthesia. Then, the mice were allowed to 
recover for 5 days with one heparin flush on day 3 before undergoing the clamp 
procedure. All mice were fasted overnight to synchronize the metabolic state. On 
the day of the procedure, mice were single-housed in a standard housing cage 
with a tether arm attached to the catheter. A dual infusion pump (Harvard 
Apparatus, MA) was used to infuse insulin at a constant flow rate. A glucose 
solution was infused at a variable rate to maintain glucose at a target value of 
75-110 mg/dl and held at that level for 60 minutes. The procedure takes an 
average of 90-100 minutes. A comparable rate of saline infusion was used as 
control. Glucose was monitored using tail vein blood at 5-min intervals with a 
glucometer (Glucometer Elite, Tarrytown, NY). Final insulin concentration was 
measured to ensure the success of the clamp, using the MAGPIX method 
(Luminex, Austin, TX).
Substrate metabolism in ex vivo working hearts
Hearts were rapidly excised in ice-cold buffer. The aorta was then 
cannulated, and the heart was perfused in the working mode at a constant 
pressure of 60 mm Hg with Krebs buffer containing 0.4 mM palmitate prebound to 
3% BSA (Bovine Serum Albumin) at 37° C saturated with 95% O2 and 5% CO2 as 
previously described (118, 119). Palmitate oxidation (POX) was determined by
3 3measuring the amount of 3H2O released from [9,10-3H] palmitate (Perkin Elmer, 
Waltham, Massachusetts). Glycolysis and glucose oxidation were determined by
3 3measuring the amount of 3H2O released from the metabolism of [5-3H] glucose
1 4(Perkin Elmer, Waltham, Massachusetts) and CO2 released by the metabolism
14of [ U - C ]  glucose (Perkin Elmer, Waltham, Massachusetts), respectively. Cardiac 
output, cardiac efficiency and MVO2were determined as previously described 
(119).
Mitochondrial respiration
Fibers were separated from the left ventricle and permeabilized with 
saponin (Sigma, St. Louis, MO) as previously described (120). Oxygen 
consumption was measured at 25 °C as V0 in buffer supplemented with 20 ^M 
Palmitoyl-carnitine (PC respiration) or 10 mM pyruvate (PM respiration). Then 
ADP and oligomycin were added in sequence for measuring VADP and Voligo. The 
rate of ATP synthesis was determined by sampling the respiratory buffer six times
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at 10 second intervals shortly after adding ADP. Final respiration rates were 
normalized by dry heart fiber weight.
Mitochondrial DNA quantification
DNA was extracted from 5 mg heart tissue and purified with DNeasy Tissue 
kit (Invitrogen, Carlsbad, CA). Real-time PCR was performed using an ABI Prism 
qPCR instrument (Applied Biosystems, Foster City, CA) in a 96-well plate format 
with SYBR Green I for detection. Mitochondrial DNA content (D-loop noncoding 
region) was expressed relative to genomic Ndufv1. Primers for mitochondrial 
D-loop noncoding region and genomic Ndufv1 gene were obtained from a 
previous publication (78).
Electron microscopy
Cardiac tissue samples were removed and fixed in EM fixation buffer 
containing 2.5% glutaraldehyde and 1% paraformaldehyde. They were processed 
as previously described at University of Utah EM core (120).
Echocardiography
Echocardiography was done as previously described (121). In detail, mice 
were anesthetized with isoflurane and placed on a heated stage (37 °C). Chest 
hair was then removed with a topical depilatory agent before the echocardiogram.
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Short and long axis two-dimensional guided M-mode images were taken with a 13 
MHz linear probe from GE Medical Systems (Milwaukee, WI) for the 
measurements of left ventricular dimensions and wall thickness. Fractional 
shortening [%] was calculated as 100*[(LVDd - LVDs) / LVDd]. LVDd: left 
ventricular dimension-diastolic; LVDs: left ventricular dimension-systolic.
Cardiac catheterization
Cardiac catheterizations were performed as previously described (121). 
Mice were anesthetized with a single intraperitoneal injection of 400 mg chloral 
hydrate per 1 kg of body weight and placed on a heating pad (37 °C). A Millar 
Mikro-Tip catheter (1.0F; Millar Instruments, Houston TX) was then inserted into 
the left ventricle via the right carotid artery, and hemodynamic measurements 
(maximum and minimum dp/dt) were obtained using LabChart7 Pro software 
(ADInstruments, Colorado Springs, CO).
Statistics
Data are expressed as the mean ± SE (n>3). Statistical significance of two 
different groups was evaluated by Student-t test. Statistical significance of more 
than two groups with one independent variable was estimated by a one-way 
ANOVA followed by Bonferroni post-hoc test. P<0.05 was considered significant.
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Results
Cardiac specific deletion of mTOR
Cardiac mTOR deletion was achieved by doxycycline induced cardiac 
specific overexpression of Cre recombinase. Four weeks after first doxycycline 
injection, there was an 83.2% decrease of mTOR protein in whole heart 
homogenates from mTOR KO mice compared to controls, while in other tissues 
such as liver and skeletal muscle, mTOR protein levels were maintained (Fig 3-1A, 
B). mTOR mRNA was also reduced by 90.9% in mTOR KO hearts compared to 
control hearts (Fig 3-1C).
Without insulin treatment, phosphorylation of Akt on both Ser473 and 
Thr308 residues was barely detectable in control hearts, and phosphorylation of 
mTORC1 downstream targets S6, 4E-BP1 was also low. mTOR deletion in the 
heart did not further decrease the phosphorylation on Akt Ser473, S6 and 4E-BP1. 
In contrast, mTOR deletion increased Akt Thr308 phosphorylation. Insulin robustly 
increased Akt phosphorylation on both Ser473 and Thr308 sites, resulting in an 
increase of S6 and 4E-BP1 phosphorylation in control hearts. Deletion of mTOR 
reduced insulin stimulated Akt Ser473 phosphorylation by 42.2% compared to 
control hearts stimulated with insulin, while insulin stimulated Akt Thr308 
phosphorylation in mTOR KO heart was comparable to control hearts, supporting 
the fact that mTORC2 specifically phosphorylates Akt on the Ser473 residue. 
Insulin stimulated S6 phosphorylation and 4E-BP1 phosphorylation (top band)
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Control mTOR KO Control mTOR KO
Figure 3-1: Generation and verification of mTOR deletion in mTOR KO mice. A. 
Western blotting of mTOR, raptor and rictor in heart, liver and skeletal muscle 
from mTOR KO mice. B. Quantification of mTOR protein level in mTOR KO hearts.
n=4. C. mRNA measured by qRT-PCR in mTOR heart tissue. n=6. **:p<0.01.
were also reduced by 62.6% and 41.0% respectively in mTOR KO hearts, 
confirming that the deletion of mTOR also resulted in a decrease of mTORC1 
signaling in the heart (Fig 3-2).
Myocardial metabolism and substrate oxidation
Cardiac output, cardiac power, and aortic pressure measured in ex vivo 
working hearts were not changed 4 weeks after doxycycline treatment, 
suggesting that there was no cardiac dysfunction in mTOR KO hearts (Figure 3-3). 
Myocardial fatty acid oxidation (FAO) was reduced by 16.4%, and oxygen 
consumption was reduced by 24.9% in mTOR KO hearts compared to control 
hearts, at the same time cardiac efficiency was increased by 57.1% (Fig 3-3). 
Transcription of fatty acid utilization genes such as fatty acid binding protein 3 
(FABP3), medium-chain acyl-CoA dehydrogenase (MCAD), and hydroxyacyl-CoA 
dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (trifunctional 
protein) alpha subunit and beta subunit (HADHA, HADHB) were repressed in 
mTOR KO hearts (Fig 3-4). Although carnitine palmitoyltransferase (CPT) 
transcript levels were not changed, CPT1 and CPT2 enzymatic activity measured 
in vitro, was decreased by 41% and 32%, respectively (Fig 3-5). Altogether 
suggests that impaired fatty acid oxidation occurs at multiple levels including fatty 
acid transport into mitochondria as well as beta oxidation within the mitochondria. 
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Figure 3-2: Insulin stimulated Akt, S6 and 4E-BP1 phosphorylation in control and 
mTOR KO hearts. There are three bands for 4E-BP1 blot, the lowest band is 
nonphosphorylated 4E-BP1, the middle band is the phosphorylated 4E-BP1, and 
the highest band is hyper-phosphorylated 4E-BP1. Phosphorylation of 4E-BP1 by 
insulin leads to a shift from lower band to higher band.
74
Figure 3-3: Cardiac substrate oxidation in mTOR KO hearts measured in ex vivo 
working hearts. n=5-7. *: p<0.05, **: p<0.01.
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Figure 3-4: Expression of genes for fatty acid transport and fatty acid metabolism





















Figure 3-5: CPT enzymatic activity in isolated mitochondria. n=4. *: p<0.05.
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Control mTOR KO
Figure 3-6: A. PGC1a and PGC1 p gene expression measured by qPCR in mTOR
deficient hearts. n=6. B. PGC1a protein level in control and mTOR KO heart
measured by western blotting. n=4.
and PGC-1a protein level was also not changed (Fig 3-6B), suggesting the 
decrease of MCAD, FABP3, HADHA and HADHB were regulated independently 
of PGC expression.
Glycolysis was preserved in mTOR KO hearts (Fig 3-3). Glycolysis is a 
multiple-step, multiple enzyme-catalyzed process, occurring after the initial 
transport of glucose into cells. Unchanged GLUT1 and GLUT4 gene expression 
and protein content (Fig 3-7A,B) indicate preserved glucose uptake capability in 
mTOR KO hearts, which agrees with unchanged glycolysis. Despite unchanged 
glycolysis, glucose oxidation in mTOR KO hearts was increased by 53.7% (Fig 
3-3). Glucose oxidation levels can be regulated by pyruvate dehydrogenase 
kinases (PDK), which phosphorylate pyruvate dehydrogenase (PDH) to inactivate 
its enzymatic activity. However, all four known isoforms of PDK in the heart were 
not changed in mTOR KO hearts relative to control hearts. Phosphorylation of 
PDH on Ser293 residue was not changed either (Fig 3-7C), ruling out regulation 
of PDH activity by phosphorylation in mTOR KO hearts. PDH can also be 
regulated allosterically by metabolites, and reduced acetyl-coA from lowering fatty 




Figure 3-7: Glucose transporters, pyruvate dehydrogenase (PDH) and pyruvate 
dehydrogenase kinases (PDKs) were not changed in mTOR KO hearts. A. 
Expression of GLUT1 and GLUT4 measured by qPCR. n=6. B. GLUT1 and 
GLUT4 protein levels measured by western blotting. n=6. C. All four cardiac PDK 
isoforms, phospho-PDH and total PDH protein levels measured by western 
blotting.
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Myocardial mitochondrial respiration and morphology
To investigate if a reduced FAO is secondary to impaired mitochondrial 
substrate oxidation, oxygen consumption rates were measured in 
saponin-permeabilized cardiac fibers, supplemented with different substrates. 
Consistent with a reduction in FAO, mitochondrial respiration with 
palmitoyl-carnitine was reduced by 20.0% in mTOR KO heart fibers. As a result of 
reduced respiration, ATP production was reduced by 18.9%. However, the ATP/O 
ratio was not changed, indicating the decrease in ATP production is independent 
of mitochondrial uncoupling in mTOR KO hearts (Fig 3-8). When isolated mTOR 
KO cardiac fibers were supplemented with pyruvate, respiration rates were similar 
to fibers from control hearts. ATP production and ATP/O were also unchanged 
(Fig 3-9). Carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) is a 
mitochondrial uncoupler which maximizes mitochondrial respiration, so FCCP 
respiration rate can be used as an indicator of maximal mitochondrial oxidation 
capacity. 1 uM FCCP, in the presence of ADP and pyruvate, stimulated oxygen 
consumption equivalently in control fibers and mTOR KO fibers, indicating the 
preserved electron transport chain activity in mTOR KO hearts (Fig 3-9).
Mitochondrial DNA content was not reduced in mTOR KO hearts (Fig 
3-10A), mitochondrial citrate synthase activity was also maintained (Fig 3-10B). 
Ultrastructure revealed by electron microscopy showed a normal alignment of 
mitochondria in mTOR deficient hearts and normal mitochondrial cristae structure
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Figure 3-8: Mitochondrial respiration supplemented with palmitoyl-carnitine. V0 is 
basal respiration, VADP is respiration after adding of ADP, VFCCP is respiration after 
adding of FCCP, VOligo is respiration after adding of oligomycin. ATP is ATP 
generation from fibers supplemented with indicated substrate and ATP/O ratio is 
the ATP generation normalized by oxygen consumption of the fibers, which is an
indicator of mitochondrial uncoupling. *: p<0.05.
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Figure 3-9: Mitochondrial respiration supplemented with pyruvate. Vo is basal 
respiration, VADP is respiration after adding of ADP, VFCCP is respiration after 
adding of FCCP, VOligo is respiration after adding of oligomycin. ATP is ATP 
generation from fibers supplemented with indicated substrate and ATP/O ratio is 
the ATP generation normalized by oxygen consumption of the fibers, which is an
indicator of mitochondrial uncoupling. *: p<0.05.
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Figure 3-10: Mitochondrial DNA content, citrate synthase activity and 
mitochondrial morphology were not changed in mTOR KO hearts. A. 
Mitochondrial DNA content measured by qPCR in control and mTOR KO hearts.
n=8. B. Mitochondrial citrate synthase (CS) activity measured in control and
mTOR KO hearts. n=5-6. C. Mitochondrial ultrastructure revealed by EM.
(Fig 3-10C). Protein levels of representative mitochondrial complex proteins were 
not reduced (Fig 3-11). Taken together, mTOR deletion does not result in global 
mitochondrial dysfunction but specifically precipitates a defect in FAO.
Development of cardiac dysfunction and demise of the mTOR KO mice
Consistent with ex vivo cardiac function measurement in working hearts, 
cardiac function evaluated by echocardiography showed that fractional shortening 
in mTOR KO hearts was maintained up to 4 weeks following doxycycline 
treatment (Fig 3-12A). Heart weight normalized to body weight was not changed 
(data not shown). Maximum dp/dt and minimum dp/dt of mTOR KO hearts 
measured by cardiac catheterization also showed no change (Fig 3-12B). 
However, 6 weeks after doxycycline treatment, the mTOR KO mice had a 26.5% 
decrease in fractional shortening, suggesting an impaired cardiac function (Fig 
3-12A). Shortly thereafter, the mTOR KO mice started to die; and by 10 weeks 
following doxycycline treatment, all the mTOR KO mice are dead (Fig 3-12C), 
supporting an indispensable role of mTOR in the adult heart.
Discussion
mTOR regulates many aspects of cell physiology in vivo, including but not 
limited to protein synthesis, proliferation, autophagy and mitochondrial biogenesis 
(108). So it is not surprising that deletion of mTOR in mice resulted in lethality of
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Figure 3-11: Representative mitochondrial complex proteins revealed by western
blotting.
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Figure 3-12: Development of cardiac dysfunction in mTOR KO hearts and 
lethality of the mice. A. Serial echocardiography of control and mTOR KO mice. 
n=5-8. B. Cardiac hemodynamic parameters measured by catheterization 4 
weeks following doxycycline treatment. n=6-7. C. Survival curve of mTOR KO 
mice following DOX treatment. n=9-10. D. LC3 western blots of control and mTOR 


















the embryo shortly after implantation (68, 69). The role of mTOR is distinct in 
different tissues, and it is indispensable for the heart, but the mechanism by which 
deletion of mTOR in the heart leads to cardiac failure is not clear (109).
In this study, deletion of mTOR by doxycycline induced TetO expression in 
the adult hearts leads to cardiac failure and death of mice, agreeing with previous 
publication that mTOR is indispensable in maintaining cardiac function and 
survival (109). However, similar to raptor deletion in the heart (78), we did not 
observe an increase of total 4E-BP1, suggesting that an uncontrolled increase of 
4E-BP1, particularly the nonphosphorylated form, might not be the primary cause 
of heart failure in mTOR deficient hearts.
We initially hypothesized that deletion of mTOR would result in a reduction 
of PGC-1a, and thus a decrease of total mitochondrial respiratory capacity. 
However, we did not observe either a decrease of PGC-1a mRNA or proteins, 
which are similar to findings in raptor deficient hearts in which PGC-1 a expression 
is preserved 2 weeks after the raptor deletion (78). In fact, a role for the mTOR in 
the transcriptional regulation of PGC-1a is controversial. Although a mechanism 
by which mTORCI- PGC-1a-YY1 regulates expression of mitochondrial 
biogenesis genes including PGC-1a itself in skeletal muscle and C2C12 cells was 
proposed (47), a direct interaction of endogenous mTORCI, PGC-1a and YY1 is 
not supported by fractionation and imaging studies, revealing relatively low or 
absent endogenous mTORCI in the nucleus (123-125). In our study, we did not
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observe any change of PGC-1a at both RNA and protein levels. And the 
preserved mitochondrial FCCP respiration, normal levels of OXPHOS 
mitochondrial proteins and normal mitochondrial morphology argue against a 
primary role for mTOR in the regulation of global mitochondrial biogenesis. Thus, 
the possibility exists that damaged mitochondria in MCM-mTOR or raptor 
deficient hearts (78, 109) were secondary to the effect of cardiac dysfunction or 
failure, or a combination of adverse effects of mTOR or raptor deletion acting in 
concert with tamoxifen treatment.
Attempts to increase PGC-1 expression or activity have also failed to 
rescue the myopathic phenotypes of mice with skeletal muscle deletion of raptor. 
Bezafibrate, a PPARpan-agonist that activates the PPAR/PGC-1a pathway, was 
used on skeletal muscle raptor deficient mice. Although bezafibrate increased 
mitochondrial function, such as oxidative capacity and expression of 
mitochondrial genes, it did not prevent the progression of myopathy. Moreover, 
Genetic overexpression of PGC-1a did not reverse myopathy either (126). Taken 
together, these observations suggest that deletion of mTOR induced myopathy is 
not regulated through PGC-1a, which could also be true in the heart.
Another possible mechanism by which mTOR deletion could induce heart 
failure is unrestrained autophagy. It is possible that deletion of mTOR in the heart 
results in excessive autophagy, given the role that mTOR plays in the suppression 
of autophagy. However, there was no change of autophagy as measured by
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LC3-II levels in mTOR KO hearts (Fig 3-12D), and transmission electron 
microscopy also shows no increase of autophagosome formation in mTOR KO 
hearts relative to control hearts.
In the present study, the earliest change observed in mTOR KO hearts is 
reduced FAO, reduced mitochondrial palmitoyl-carnitine respiration and ATP 
generation. The heart has an extraordinarily high level of metabolism and heavily 
relies on fat as the source of ATP, thus a subtle change in fatty acid metabolism 
and ATP production could result in a profound cumulative impact on cellular 
energetics (127), which is crucial to be maintained at a normal level for protein 
synthesis, cellular damage repair and many cellular physiological functions in 
cardiomyocytes. Transportation of fatty acid especially long chain fatty acid by 
CPT into mitochondria is a rate limiting step for FAO; despite maintained CPT 
transcript levels (Figure 4-3A) and protein levels (data not shown), CPT activities 
were reduced (Figure 4-3B), suggesting the regulation of CPT1 activity might 
result from posttranscriptional modification. It has been shown that oxidation of 
CPT1 would reduce CPT1 activity (128); however, there was no increase of 
hydroxynonenal-CPT1 adducts (data not shown), indicating no increase of CPT-1 
oxidation in mTOR KO hearts. CPT1 can also be phosphorylated, acetylated or 
nitrated (129), but the effect of those modifications on CPT1 enzymatic activity 
was not known.
So far it is clear that mTOR is essential for cardiac survival and function.
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Many hypotheses have been proposed to explain how deletion of mTOR leads to 
heart failure in the mice; however, there has not been a full rescue by any 
measurement. So we postulate that there might be no single gene that can rescue 
the mTOR KO heart simply because mTOR controls so many aspects of cell 
physiology through so many different targets. An interesting observation is that 
chronic rapamycin treatment did not lead to heart failure as opposed to mTOR KO 
hearts (130). So a comparison of gene expression and phospho-proteomics 
should yield unique targets that were regulated by mTOR deletion but not by 
rapamycin treatment in the heart, and those genes/proteins would have a greater 




Insulin signaling pathway not only engages in regulation of responses of 
cardiomyocytes to insulin, but also plays an important role in cardiac survival, 
metabolism and functioning. Akt and mTOR are two important kinases in insulin 
signaling cascades. The role of Akt and mTOR in development of cardiac insulin 
resistance has been controversial and the role of mTOR in cardiac development 
and metabolism has not yet been established. This dissertation used several lines 
of mice to address those questions in the heart.
Cardiac insulin resistance is an independent risk factor for heart disease. 
Unlike skeletal muscle, PI3K-Akt signaling is persistently activated in cardiac 
muscle, despite a reduction in glucose uptake. Given that persistent activation of 
PI3K and Akt in the heart may be a consequence of hyperinsulinemia in insulin 
resistant states, the study in Chapter 2 was designed to determine if constitutive 
activation of PI3K and Akt signaling in the heart could independently impair 
insulin-mediated glucose uptake and GLUT4 translocation. The study was initially 
predicated on the hypothesis that chronic activation of PI3K and Akt signaling 
would activate mTORC1-mediated S6K-IRS negative signaling feedback and 
desensitize insulin-mediated glucose transport. Unexpectedly, the study 
discovered that PI3K-Akt activation impaired myocardial glucose uptake prior to 
any evidence of S6K activation in cardiomyocytes despite normal translocation of 
GLUT4. These data indicate that activation of PI3K and Akt may impair glucose 
uptake via mechanisms that impair the intrinsic activity of the GLUT4 transporter.
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Future studies on the mechanism of GLUT4 activation will guide pharmaceutical 
companies to develop GLUT4 activators which might be a therapy for certain 
heart disease by increasing cardiac glucose uptake.
Insulin signaling and many other cellular signaling pathways converge at 
mTOR, which has been intensively studied in cell culture and different mouse 
tissues. In Chapter 3, an inducible and cardiac specific mTOR deficient mouse 
model was generated for studying the role of mTOR in cardiomyocyte 
bioenergetics. A decrease in fatty acid but not glucose utilization, which leads to a 
decrease in ATP production, was identified in the mTOR deficient heart prior to 
development of cardiac dysfunction. Fatty acid utilization genes were also 
downregulated in mTOR deficient heart, but independently of PGC. However, 
whether this downregulation in fatty acid utilization leads to cardiac failure is 
inconclusive. Future study should test the effect of restoring the cardiac fatty acid 
utilization and ATP production in mTOR deficient heart. Last, an interesting 
observation is that chronic rapamycin treatment did not lead to heart failure as 
opposed to mTOR KO hearts. So a comparison of phosphoproteome should be 
helpful in finding unique mTOR targets that were not blocked by rapamycin 
treatment, the targets that could have greater relevance in the regulation of 
cardiac metabolism in murine hearts.
Altogether this dissertation has advanced our understanding of insulin
96
signaling pathway especially Akt-mTOR signaling axis in regulation of GLUT4 
translocation, glucose uptake as well as cardiac bioenergetics.
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